Furthermore, the study found that TRAP1/HSP90 inhibitors led to a decrease in BRAF, with this effect appearing more pronounced in colorectal tumor cell lines with the BRAFV600E mutation, suggesting that TRAP1 plays a key role in maintaining BRAF expression [42]. Here, BRAF is linked to colorectal neoplasm.